0.02
-0.00445(-22.25%)
Currency In USD
| Previous Close | 0.02 |
| Open | 0.02 |
| Day High | 0.02 |
| Day Low | 0.02 |
| 52-Week High | 0.47 |
| 52-Week Low | 0 |
| Volume | 1,012 |
| Average Volume | 2,438 |
| Market Cap | 75,493 |
| PE | 0 |
| EPS | -34.51 |
| Moving Average 50 Days | 0.02 |
| Moving Average 200 Days | 0.18 |
| Change | -0 |
If you invested $1000 in Panbela Therapeutics, Inc. (PBLA) since IPO date, it would be worth $0 as of December 04, 2025 at a share price of $0.016. Whereas If you bought $1000 worth of Panbela Therapeutics, Inc. (PBLA) shares 5 years ago, it would be worth $0 as of December 04, 2025 at a share price of $0.016.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Panbela Provides Business Update and Reports Q3 2024 Financial Results
GlobeNewswire Inc.
Nov 14, 2024 9:10 PM GMT
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
GlobeNewswire Inc.
Oct 31, 2024 12:00 PM GMT
MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
GlobeNewswire Inc.
Sep 24, 2024 12:00 PM GMT
MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient e